Psilocybin-assisted psychotherapy for the treatment of depression and anxiety associated with life-threatening illness

St. Vincent's Hospital Melbourne0 个研究点目标入组 35 人开始时间: 2019年9月5日最近更新: 2024年9月9日

适应症

试验速览

暂无简介。

•Adults aged between 18-85 years with a life - threatening illness, under the care of a specialist physician; proficient in English (funds available for this research would preclude access to translators to enable non-English speaking participants); Experiencing psychological distress that was precipitate or augmented by their life-threatening illness; AKPS of 50 or above (or if participant is immobile but deemed physically well enough to participate by the study doctor and their treating physician, scores lower than 50; upon receipt of medial clearance from the potential participants primary treating physician and being screened by the study doctor and being deemed eligible.
•Examples of eligible conditions include metastatic malignant diseases, end stage respiratory disease, end stage renal failure, incurable but indolent cancers that have a high likelihood of returning.

•Diseases with major CNS involvement
•Hepatic dysfunction
•Known paraneoplastic syndrome or ectopic hormone production
•Uncontrolled cardiovascular condtions, unstable angina, atrial fibrillation, TIA
•Patients who are respirator dependent or intubated.
•A diagnosis of epilepsy or known previous seizure activity
•Renal insufficiency
•Insulin dependent diabetes
•Females who are pregnant, nursing, or attempting to become pregnant
•Patients taking SSRI or SNRI (participant may be eligible if they would like to wean and cease under supervision and if deemed safe to do so)
•Participants taking medications including:
•Rifamycin, rifampin, rifabutin, rifapentine, carbamazepine, phenytoin, phenobarbital, nevirapine, efavirenz, paclitaxol, St John's Wort, - all HIV protease inhibitors, itraconazole, ketoconazole, erythromycin, clarithromycin, troleandomycin.
•PSYCHIATRIC - Severity of depression or anxiety symptoms that would warrant immediate hospitalisation (including acute suicidality); current or past history of psychosis/psychotic disorder, current or past history of bipolar disorder; first degree relative with psychosis or bipolar disorder; current or past history of alcohol or substance dependence (excluding caffeine or nicotine) in the past 5 years; Axis II conditions that may not e compatible with the treatment protocol (determined by clinical interview).

发起方

St. Vincent's Hospital Melbourne